Published on in Vol 10, No 3 (2021): March

Preprints (earlier versions) of this paper are available at https://preprints.jmir.org/preprint/25966, first published .
Interprofessional Medication Adherence Program for Patients With Diabetic Kidney Disease: Protocol for a Randomized Controlled and Qualitative Study (PANDIA-IRIS)

Interprofessional Medication Adherence Program for Patients With Diabetic Kidney Disease: Protocol for a Randomized Controlled and Qualitative Study (PANDIA-IRIS)

Interprofessional Medication Adherence Program for Patients With Diabetic Kidney Disease: Protocol for a Randomized Controlled and Qualitative Study (PANDIA-IRIS)

Journals

  1. Pasquier J, Schneider M, Locatelli I. Estimation of adherence to medication treatment in presence of censoring. British Journal of Clinical Pharmacology 2023;89(7):1928 View
  2. Bandiera C, Pasquier J, Locatelli I, Niquille A, Wuerzner G, Dotta-Celio J, Hachfeld A, Wandeler G, Wagner A, Csajka C, Zanchi A, Cavassini M, Schneider M. Medication Adherence Evaluated Through Electronic Monitors During the 2020 COVID-19 Pandemic Lockdown in Switzerland: A Longitudinal Analysis. Patient Preference and Adherence 2022;Volume 16:2313 View
  3. Bandiera C, Lam L, Locatelli I, Dotta-Celio J, Duarte D, Wuerzner G, Pruijm M, Zanchi A, Schneider M. Understanding reasons and factors for participation and non-participation to a medication adherence program for patients with diabetic kidney disease in Switzerland: a mixed methods study. Diabetology & Metabolic Syndrome 2022;14(1) View
  4. Liao M, Chen S, Guo R. Association between carotid ultrasonographic parameters and microvascular and macrovascular complications in diabetes: A systematic review and meta-analysis. Journal of Diabetes and its Complications 2023;37(8):108554 View
  5. Bandiera C, Dotta-Celio J, Locatelli I, Nobre D, Wuerzner G, Pruijm M, Lamine F, Burnier M, Zanchi A, Schneider M. The differential impact of a 6-versus 12-month pharmacist-led interprofessional medication adherence program on medication adherence in patients with diabetic kidney disease: the randomized PANDIA-IRIS study. Frontiers in Pharmacology 2024;15 View